BioCryst Pharmaceuticals, Inc. (BCRX)
NEUTRALFundamental
63
Price
$9.84
Market Cap
$2.43B
Part 1 · What the company is worth
Overview
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$941M
Trailing 12 months (through 6/30/2026)
Net Income
$-385M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$345M
Total Equity
$-119M
Total Liabilities
$633M
Current Ratio
2.32
Interest Coverage
4.16
Debt/EBITDA
1.20
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$26.93
Current Price
$9.84
Margin of Safety
+63.5%
Fair Value Range
$20.10 - $33.76
Estimation Methods
Valuation Metrics
P/E Ratio
7.86
ROE
-221.4%
P/B Ratio
-
P/FCF
6.62
Gross Margin
97.8%
ROIC
-70.9%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-70.9%
WACC
9.0%
ROIC − WACC
-79.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (13)
- EPS shows upward trend
- Gross Margin 97.8%
- P/FCF 6.62
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Low reliance on intangibles
- DCF valuation (Undervalued)
- Revenue Growth 5Y 117.9%
- Analyst Consensus 88% Buy
- Piotroski F-Score 7/9
Failed (8)
- Price CAGR 4.20%
- ROIC -70.9%
- Operating Margin -33.3%
- Return on Tangible Assets
- ROE -328.8%
- Earnings Surprise avg -35.2%
- Share Dilution 5.5%
- Net Margin Trend -40.9% vs -6.4%
Unavailable (6)
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Strong financial health
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Charles K. Gayer | CEO, President & Director | 54 |
| Mr. Babar Ghias | CFO & Head of Corporate Development | 46 |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 59 |
| Mr. John Ruesch | Chief Technical Operations Officer | - |
| Dr. David W. Jenkins M.A., Ph.D. | Chief Scientific Officer | - |
| Nick Wilder | Manager of Investor Relations | - |
| Ms. Stephanie Angelini | Chief People Officer & Chief Communications Officer | - |
| Dr. William P. Sheridan MBBS | Chief Development Officer | 70 |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer | 72 |
| Ms. Jinky Ang Rosselli | Chief Data Innovation Officer | - |
Audit Risk
8
Board Risk
3
Compensation Risk
10
Shareholder Rights Risk
8
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for BCRX, sourced from Markets Gazette.
- 5/6/2026NEUTRALFull Transcript: BioCryst Pharma Q1 2026 Earnings Call
BioCryst Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. The transcript, which is available for review, details the company's financial performance and strategic outlook for the first quarter of 2026. Investors and analysts can access the full transcript to gain insights into the company's operational updates, pipeline progress, and future guidance. As this is an informational event, no immediate market reaction is implied without further specific financial data or forward-looking statements being disclosed within this summary.
via Markets Gazette